Gland Pharma Limited

rs 25

IMITED November 06, 2023 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limi

32%

s (1/4) Revenue from Operations (INR Mn) Gross Profit (1) / Gross Profit Margin (2) (INR Mn / %) 32% 25,821 19,013 10,444 12,087 13,734 62% 7,558 63% 5,249 50% 6Oo , ° 16,077 62% 8,519

62%

oss Profit (1) / Gross Profit Margin (2) (INR Mn / %) 32% 25,821 19,013 10,444 12,087 13,734 62% 7,558 63% 5,249 50% 6Oo , ° 16,077 62% 8,519 62% 10,078 53% Q2 FY23 Q1 FY24 Q2 FY24

63%

1) / Gross Profit Margin (2) (INR Mn / %) 32% 25,821 19,013 10,444 12,087 13,734 62% 7,558 63% 5,249 50% 6Oo , ° 16,077 62% 8,519 62% 10,078 53% Q2 FY23 Q1 FY24 Q2 FY24 6M FY23 6M

50%

rofit Margin (2) (INR Mn / %) 32% 25,821 19,013 10,444 12,087 13,734 62% 7,558 63% 5,249 50% 6Oo , ° 16,077 62% 8,519 62% 10,078 53% Q2 FY23 Q1 FY24 Q2 FY24 6M FY23 6M FY24 Q2 FY2

53%

013 10,444 12,087 13,734 62% 7,558 63% 5,249 50% 6Oo , ° 16,077 62% 8,519 62% 10,078 53% Q2 FY23 Q1 FY24 Q2 FY24 6M FY23 6M FY24 Q2 FY23 Q1 FY24 Q2 FY24 6M FY23 6M FY24 EBITDA (

30%

23 6M FY24 EBITDA (3) / EBITDA Margin (4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 5,668 30% 6,187 24% 2,969 28% 2,982 25% 7 % 3,205 23% 27% 2,412 23% - 2 0 % 1,941 16% 1,941

24%

EBITDA (3) / EBITDA Margin (4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 5,668 30% 6,187 24% 2,969 28% 2,982 25% 7 % 3,205 23% 27% 2,412 23% - 2 0 % 1,941 16% 1,941 14% 4,704

28%

/ EBITDA Margin (4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 5,668 30% 6,187 24% 2,969 28% 2,982 25% 7 % 3,205 23% 27% 2,412 23% - 2 0 % 1,941 16% 1,941 14% 4,704 25% 3,882

25%

gin (4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 5,668 30% 6,187 24% 2,969 28% 2,982 25% 7 % 3,205 23% 27% 2,412 23% - 2 0 % 1,941 16% 1,941 14% 4,704 25% 3,882 15% Q2 FY23

7 %

4) (INR Mn / %) PAT / PAT Margin (5) (INR Mn / %) 5,668 30% 6,187 24% 2,969 28% 2,982 25% 7 % 3,205 23% 27% 2,412 23% - 2 0 % 1,941 16% 1,941 14% 4,704 25% 3,882 15% Q2 FY23 Q1

23%

%) PAT / PAT Margin (5) (INR Mn / %) 5,668 30% 6,187 24% 2,969 28% 2,982 25% 7 % 3,205 23% 27% 2,412 23% - 2 0 % 1,941 16% 1,941 14% 4,704 25% 3,882 15% Q2 FY23 Q1 FY24 Q2 FY2

“❖ Some of the present low-margin businesses will be phased out to make way for newly secured businesses.”

“In the medium term, we anticipate Cenexi to begin churning results consistent with the acquisition thesis.”

“▪ We expect the RoW demand to remain stable as we align strengths to expand our market reach and establish new partnerships.”

Corporate Office

2

Regd. Office

1

Regd. Office

Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Tel: +91-40-30510999 Fax: +91-40-30510800 India

Corporate Office

Plot N o . 11 & 84, T S I I C Phase: I V Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND PHARMA LIMITED Gland Pharma Limited Financial Results Q2’FY24 06th November 2023 Cemcitibii lajectiM ■ Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from thes

Corporate Office

Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India BSE 543245 ®NSE GLAND Bloomberg GLAND:IN 14